Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study

Tugal-Tutkun I., PAVESIO C., DE CORDOUE A., BERNARD-POENARU O., Gül A.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.26, sa.7, ss.1023-1033, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/09273948.2017.1421233
  • Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1023-1033
  • Anahtar Kelimeler: Behcet's disease, gevokizumab, interleukin-1 beta, ocular exacerbation, uveitis, XOMA 052, INTERLEUKIN-1-BETA, STANDARDIZATION, RECOMMENDATIONS, POLYMORPHISMS, MULTICENTER, ADALIMUMAB, MANAGEMENT, CYTOKINES, DIAGNOSIS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose: The purpose of this article is to demonstrate the superiority of gevokizumab as compared to placebo, on top of current standard of care, in reducing the risk of Behcet's disease uveitis (BDU) exacerbations.